Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 19
2022 180
2023 41
2024 2

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35896523

222 results

Results by year

Filters applied: . Clear all
Page 1
Differential neutralization and inhibition of SARS-CoV-2 variants by antibodies elicited by COVID-19 mRNA vaccines.
Wang L, Kainulainen MH, Jiang N, Di H, Bonenfant G, Mills L, Currier M, Shrivastava-Ranjan P, Calderon BM, Sheth M, Mann BR, Hossain J, Lin X, Lester S, Pusch EA, Jones J, Cui D, Chatterjee P, Jenks MH, Morantz EK, Larson GP, Hatta M, Harcourt JL, Tamin A, Li Y, Tao Y, Zhao K, Lacek K, Burroughs A, Wang W, Wilson M, Wong T, Park SH, Tong S, Barnes JR, Tenforde MW, Self WH, Shapiro NI, Exline MC, Files DC, Gibbs KW, Hager DN, Patel M, Halpin AL, McMullan LK, Lee JS, Xia H, Xie X, Shi PY, Davis CT, Spiropoulou CF, Thornburg NJ, Oberste MS, Dugan VG; SSEV Bioinformatics Working Group; Wentworth DE, Zhou B. Wang L, et al. Nat Commun. 2022 Jul 27;13(1):4350. doi: 10.1038/s41467-022-31929-6. Nat Commun. 2022. PMID: 35896523 Free PMC article.
Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
Choi A, Koch M, Wu K, Dixon G, Oestreicher J, Legault H, Stewart-Jones GBE, Colpitts T, Pajon R, Bennett H, Carfi A, Edwards DK. Choi A, et al. J Virol. 2021 Nov 9;95(23):e0131321. doi: 10.1128/JVI.01313-21. Epub 2021 Sep 22. J Virol. 2021. PMID: 34549975 Free PMC article. Clinical Trial.
Evidence for retained spike-binding and neutralizing activity against emerging SARS-CoV-2 variants in serum of COVID-19 mRNA vaccine recipients.
Carreño JM, Alshammary H, Singh G, Raskin A, Amanat F, Amoako A, Gonzalez-Reiche AS, van de Guchte A, Study Group P, Srivastava K, Sordillo EM, Sather DN, van Bakel H, Krammer F, Simon V. Carreño JM, et al. EBioMedicine. 2021 Nov;73:103626. doi: 10.1016/j.ebiom.2021.103626. Epub 2021 Oct 20. EBioMedicine. 2021. PMID: 34688034 Free PMC article.
Neutralization of SARS-CoV-2 Omicron sub-lineages BA.1, BA.1.1, and BA.2.
Evans JP, Zeng C, Qu P, Faraone J, Zheng YM, Carlin C, Bednash JS, Zhou T, Lozanski G, Mallampalli R, Saif LJ, Oltz EM, Mohler PJ, Xu K, Gumina RJ, Liu SL. Evans JP, et al. Cell Host Microbe. 2022 Aug 10;30(8):1093-1102.e3. doi: 10.1016/j.chom.2022.04.014. Epub 2022 Apr 25. Cell Host Microbe. 2022. PMID: 35526534 Free PMC article.
Vaccine-Induced Antibody Responses against SARS-CoV-2 Variants-Of-Concern Six Months after the BNT162b2 COVID-19 mRNA Vaccination.
Jalkanen P, Kolehmainen P, Haveri A, Huttunen M, Laine L, Österlund P, Tähtinen PA, Ivaska L, Maljanen S, Reinholm A, Belik M, Smura T, Häkkinen HK, Ortamo E, Kantele A, Julkunen I, Lempainen J, Kakkola L. Jalkanen P, et al. Microbiol Spectr. 2022 Apr 27;10(2):e0225221. doi: 10.1128/spectrum.02252-21. Epub 2022 Mar 9. Microbiol Spectr. 2022. PMID: 35262410 Free PMC article.
Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
Belik M, Liedes O, Vara S, Haveri A, Pöysti S, Kolehmainen P, Maljanen S, Huttunen M, Reinholm A, Lundberg R, Skön M, Österlund P, Melin M, Hänninen A, Hurme A, Ivaska L, Tähtinen PA, Lempainen J, Kakkola L, Jalkanen P, Julkunen I. Belik M, et al. Front Immunol. 2023 Jan 23;14:1099246. doi: 10.3389/fimmu.2023.1099246. eCollection 2023. Front Immunol. 2023. PMID: 36756112 Free PMC article.
Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
Gonzalez Lopez Ledesma MM, Sanchez L, Ojeda DS, Oviedo Rouco S, Rossi AH, Varese A, Mazzitelli I, Pascuale CA, Miglietta EA, Rodríguez PE, Pallarés HM, Costa Navarro GS, Caramelo JJ, Rothlauf PW, Liu Z, Bloyet LM, Cornejo Pontelli M, Rasetto NB, Wenker SD, Ramis LY, Bialer MG, de Leone MJ, Hernando CE, Bianchimano L, Ríos AS, Treffinger Cienfuegos MS, Rodriguez García DR, Longueira Y, Laufer N, Alvarez D, Ceballos A, Ochoa V, Monzani C, Turk G, Salvatori M, Carradori J, Prost K, Rima A, Varela C, Ercole R, Toro RI, Gutierrez S, Zubieta M, Acuña D, Nabaes Jodar MS, Torres C, Mojsiejczuk L, Viegas M, Velazquez P, Testa C, Kreplak N, Yanovsky M, Whelan S, Geffner J, Pifano M, Gamarnik AV. Gonzalez Lopez Ledesma MM, et al. mBio. 2022 Feb 22;13(1):e0344221. doi: 10.1128/mbio.03442-21. Epub 2022 Jan 25. mBio. 2022. PMID: 35073758 Free PMC article.
222 results